Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer

Brakora, Katherine A.; Lee, H; Yusuf, Rushdia Z.; Sullivan, Laura A.; Harris, Adrian L.; Colella, Tina; Seiden, Michael V.

doi:10.1016/j.ygyno.2004.01.050

Cited by 44 publications

(32 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Using a cDNA microarray system, it was found that osteopontin was overexpressed in the tumors and serum of women with a recent diagnosis of ovarian cancer (25). Additionally, Kim et al (26) showed that osteopontin concentrations in plasma were higher in patients with ovarian cancer as compared with healthy controls, or women with benign ovarian disease or other gynecologic cancers, thus an association between levels of osteopontin and ovarian cancer suggest that future research assessing its clinical usefulness would be worthwhile (199).…”

Section: Breast Cancer Biomarkersmentioning

confidence: 99%

The Role of Osteopontin in Tumor Progression and Metastasis in Breast Cancer

Rodrigues

Teixeira

Schmitt

et al. 2007

Cancer Epidemiology, Biomarkers &Amp; Prevention

206

144

View full text Add to dashboard Cite

The use of cancer biomarkers to anticipate the outlines of disease has been an emerging issue, especially as cancer treatment has made such positive steps in the last few years. Progress in the development of consistent malignancy markers is imminent because advances in genomics and bioinformatics have allowed the examination of immense amounts of data. Osteopontin is a phosphorylated glycoprotein secreted by activated macrophages, leukocytes, and activated T lymphocytes, and is present in extracellular fluids, at sites of inflammation, and in the extracellular matrix of mineralized tissues. Several physiologic roles have been attributed to osteopontin, i.e., in inflammation and immune function, in mineralized tissues, in vascular tissue, and in kidney. Osteopontin interacts with a variety of cell surface receptors, including several integrins and CD44. Binding of osteopontin to these cell surface receptors stimulates cell adhesion, migration, and specific signaling functions. Overexpression of osteopontin has been found in a variety of cancers, including breast cancer, lung cancer, colorectal cancer, stomach cancer, ovarian cancer, and melanoma. Moreover, osteopontin is present in elevated levels in the blood and plasma of some patients with metastatic cancers. Therefore, suppression of the action of osteopontin may confer significant therapeutic activity, and several strategies for bringing about this suppression have been identified. This review looks at the recent advances in understanding the possible mechanisms by which osteopontin may contribute functionally to malignancy, particularly in breast cancer. Furthermore, the measurement of osteopontin in the blood or tumors of patients with cancer, as a way of providing valuable prognostic information, will be discussed based on emerging clinical data. (Cancer Epidemiol Biomarkers Prev 2007;16(6):1087 -97)

show abstract

Section: Breast Cancer Biomarkersmentioning

confidence: 99%

The Role of Osteopontin in Tumor Progression and Metastasis in Breast Cancer

Rodrigues

Teixeira

Schmitt

et al. 2007

Cancer Epidemiology, Biomarkers &Amp; Prevention

206

144

View full text Add to dashboard Cite

show abstract

“…In contrast to our results, a previous study documented a significant relationship between serum levels of OPN and CA-125 in ovarian cancer patients (Spearman ρ=0.31, p＜0.01). 24 Only CA-125 showed a significant positive correlation with cancer stage (Spearman ρ=0.24, p＜0.01). Our result corresponds well with those of previous studies on CA-125.…”

mentioning

confidence: 97%

Correlation between preoperative serum levels of five biomarkers and relationships between these biomarkers and cancer stage in epithelial overian cancer

Hwang

Lee

et al. 2009

J Gynecol Oncol

View full text Add to dashboard Cite

Objective: To examine the correlation among the preoperative serum levels of five biomarkers presumed to be useful for early detection of epithelial ovarian cancer and evaluate the relationships between serum levels of these five biomarkers and epithelial ovarian cancer stage. Methods: We analyzed 56 newly diagnosed epithelial ovarian cancer patients. Preoperative serum levels of leptin, prolactin, osteopontin (OPN), insulin-like growth factor-II, and CA-125 were determined by ELISA. We also examined the correlation between the serum levels of the biomarkers and ovarian cancer stage. Significant differences in the mean serum levels of two proteins, leptin and CA-125, were observed between stage subsets. Results: There was a significant negative correlation between prolactin and leptin and a significant positive correlation between prolactin and OPN. Of the five biomarkers, only the mean serum CA-125 level showed a significant positive correlation with cancer stage (Spearman ρ=0.24, p＜0.01). OPN showed a marginally significant positive correlation with stage (Spearman ρ=0.14, p=0.07). Conclusion:We demonstrated the relationship between five biomarkers in epithelial ovarian cancer. These tumor markers may be useful in screening for ovarian cancer, in characterizing disease states, and in developing therapeutic interventions targeting these marker proteins. Large-scale studies that include potential confounding factors and modifiers are necessary to more accurately define the value of these novel biomarkers in ovarian cancer.

show abstract

“…Validation of our approach comes from the identification of several proteins that exhibit increased levels in ovarian cancer sera [e.g., HE4 (9), prostatin (6), OPN (7,8), several members of the kallikrein protein family (19), and insulin-like growth factor-2 (10)]. In this study, we focused on four genes encoding secreted proteins (MMP-7, SLPI, OPN, and KLK10), with the aim of assessing their potential usefulness as a multianalyte diagnostic test.…”

Section: Discussionmentioning

confidence: 99%

“…The primary data have been deposited and are accessible on the Gene Express Omnibus. 8 Delineation of genes encoding putative secreted proteins. Several databases were used to identify genes encoding proteins with characteristics of secretion.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

An Integrated Clinical-Genomics Approach Identifies a Candidate Multi-Analyte Blood Test for Serous Ovarian Carcinoma

Meinhold‐Heerlein

Bauerschlag

Zhou

et al. 2007

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Cancer of the ovary confers the worst prognosis among women with gynecologic malignancies, underscoring the need to develop new biomarkers for detection of early disease, particularly those that can be readily monitored in the blood. Experimental Design: We developed an algorithm to identify secreted proteins encoded among f22,500 genes on commercial oligonucleotide arrays and applied it to gene expression profiles of 67 stage I to IV serous papillary carcinomas and 9 crudely enriched normal ovarian tissues, to identify putative diagnostic markers. ELISAs were used to validate increased levels of secreted proteins in patient sera encoded by genes with differentially high expression. Results: We identified 275 genes predicted to encode secreted proteins with increased/ decreased expression in ovarian cancers (<0.5-or >2-fold, P < 0.001). The serum levels of four of these proteins (matrix metalloproteinase-7, osteopontin, secretory leukoprotease inhibitor, and kallikrein 10) were significantly elevated in a series of 67 independent patients with serous ovarian carcinomas compared with 67 healthy controls (P < 0.001, Wilcoxon rank sum test). Optimized support vector machine classifiers with as few as two of these markers (osteopontin or kallikrein 10/matrix metalloproteinase-7) in combination with CA-125 yielded sensitivity and specificity values ranging from 96% to 98.7% and 99.7% to 100%, respectively, with the ability to discern early-stage disease from normal, healthy controls. Conclusions: Our data suggest that this assay combination warrants further investigation as a multi-analyte diagnostic test for serous ovarian adenocarcinoma.

show abstract

Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer

Cited by 44 publications

References 11 publications

The Role of Osteopontin in Tumor Progression and Metastasis in Breast Cancer

The Role of Osteopontin in Tumor Progression and Metastasis in Breast Cancer

Correlation between preoperative serum levels of five biomarkers and relationships between these biomarkers and cancer stage in epithelial overian cancer

An Integrated Clinical-Genomics Approach Identifies a Candidate Multi-Analyte Blood Test for Serous Ovarian Carcinoma

Contact Info

Product

Resources

About